Clinical Trials
- Infectious Disease, Men's Health, Women's Health
Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Adults (PRIOH-1)
- Ages16 years and older
- GenderBoth
- Date04/01/2018
- HIV/AIDS, Immune System, Infectious Disease
Establish and Characterize an Acute HIV Infection Cohort in a High Risk Population
- Ages18 years and older
- GenderBoth
- Date12/08/2011
- Stomach and Esophagus, Head and Neck Cancers, Thyroid and Other Endocrine Cancers, Phase 1 Cancers
A Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Patients With HPV+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
- Ages18 years and older
- GenderBoth
- Date12/17/2019
- Orthopaedics, Muscle & Bone, Immune System
Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE (NAIVE)
- Ages18 years - 70 years
- GenderBoth
- Date10/08/2021
- Skin/Dermatology, Genetics
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita (VAPAUS)
- Ages18 years and older
- GenderBoth
- Date01/14/2022
- Infectious Disease, COVID-19 Inpatient, COVID-19 Outpatient
Using Smart Phones to Understand the Link Between Social and Geographical Context and HIV Risk Behavior Among MSM (GPS and Health)
- Ages18 years - 34 years
- GenderMale only
- Date09/01/2019
- Gynecological Cancers
A Phase II Evaluation of Afatinib
- Ages18 years and younger
- GenderFemale only
- Date05/18/2015
- COVID-19 Inpatient, COVID-19 Outpatient
COVID INSPIRE Study: funded by the CDC
- Ages18 years and older
- GenderBoth
- Date12/15/2020
- Children's Health, Diseases of the Respiratory Systems
Efficacy and Safety of OPN-375 186 ug Twice a Day (BID) in Adolescents with Bilateral Nasal Polyps
- Ages12 years - 17 years
- GenderBoth
- Date04/29/2019
- Head and Neck Cancers
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
- Ages18 years and older
- GenderBoth
- Date06/23/2015